Global Human Milk Oligosaccharides Market is anticipated to expand at a CAGR of around 21.75% CAGR By 2028
As per the recent report by MarkNtel Advisors, Global Human Milk Oligosaccharides Market is anticipated to expand at a CAGR of around 21.75% CAGR during the forecast period, i.e., 2023-28. Our report aims to provide valuable insights and assistance to clients in navigating the Global Human Milk Oligosaccharides Market, addressing key concerns pertinent to this industry. The Market is driven by increasing consumer health concerns, awareness of infant nutrition benefits, technological advancements, R&D investments, urbanization, rising incomes, changing lifestyles, government support, and diverse HMO applications in pharmaceuticals and infant products, expected to grow through 2028.
Oligosaccharides (HMO) Industry Recent Developments
- On 18 November 2022, KYOWA HAKKO BIO CO. LTD., a subsidiary of Kirin Holdings Company, Limited, completed the HMO production facility at its Thai subsidiary, THAI KYOWA BIOTECHNOLOGIES CO., LTD.
- On 31 October 2022, FrieslandCampina got approval from Australia’s & New Zealand’s authorities for using its 2’-FL trademarked Aequival in infant milk formula, i.e., in line with expanding its HMO portfolio.
Reliable Investment Segments in the Human Milk Oligosaccharides Market
Clients seeking to maximize their returns within the Human Milk Oligosaccharides market recognize the critical significance of investment decisions. Our comprehensive study delves into potential investment hubs, considering factors like projected demand, expected returns, profit margins, and market stability.
By methodically assessing these pivotal elements, clients can strategically direct their investments towards hubs that present the most auspicious opportunities. This methodical approach empowers clients to fine-tune their investment portfolio and realize sustainable growth in the global Human Milk Oligosaccharides market.
The Human Milk Oligosaccharides market analysis is segmented into various branches and further sub-segments for a comprehensive analysis, ultimately aiming to provide stakeholders with highly valuable insights. The market is segmented as follows:
- By Type (2’FL, 3’FL, 3’SL, 6’SL)
- By Application (Infant formula, Functional food & beverage, Food supplements, Others)
- By Concentration (Neutral, Acidic, Others)
- By Distribution Channel (Hypermarkets & Supermarkets, Drug store or pharmacy, Mass merchandiser, Departmental Stores, Mono-brand Store, Specialty stores)
- By Region (North America, South America, Europe, Asia-Pacific, The Middle East and Africa)
2′-FL dominates the Global Human Milk Oligosaccharides Market due to its structural similarity to human breast milk. Extensive research supports its potential health benefits for infants, and it has gained regulatory approvals for use in infant formula and baby food. Commercial production methods have evolved, and more companies are incorporating 2′-FL, driving growth in the HMO market.
Human Milk Oligosaccharides (HMOs) find their primary application in infant formula, serving as a prevalent alternative to breast milk in regions with lower breastfeeding rates. The global demand for HMOs in the formulation of infant formulas is steadily surging due to their myriad advantages, including enhanced gut health, improved memory, brain development, infection prevention, and prebiotic effects.
An increasing number of manufacturers are now incorporating HMOs into infant formula products, aiming to augment their nutritional value and provide benefits akin to breast milk. Factors such as societal shifts, the convenience of infant formula, and the growing population of working mothers worldwide are all propelling the Human Milk Oligosaccharides Market forward.
Business Partners in the Human Milk Oligosaccharides Industry
The prominent players profiled in the Global Human Milk Oligosaccharides Market research report are Biosynth Carbosynth, Chr. Hansen Holding A/S, Dextra Laboratories Ltd, DuPont Nutrition & Biosciences, Elicityl S.A., Glycosyn, Inbiose NV, Medolac Laboratories, Nestle Health Science, ROYAL DSM, BASF SE, Abbott Laboratories, GNUBIOTICS Sciences S.A., Dextra Laboratories, Others. Collaboration and partnerships play a significant role in the success of businesses in the Human Milk Oligosaccharides market.
Last years, KYOWA HAKKO BIO CO. LTD., a subsidiarfy of Kirin Holdings Company, Limited, successfully inaugurated its HMO production facility at THAI KYOWA BIOTECHNOLOGIES CO., LTD. Again, FrieslandCampina received regulatory approval from authorities in Australia and New Zealand to utilize its trademarked 2′-FL, known as Aequival, in infant milk formula, marking a strategic move to enhance its HMO product offerings.